Clinical Trial

A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa

Study acronym: Landscape
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this Phase 2 Study is to see if the investigational study drug, laruparetigene zovaparvovec, also known as AGTC-501, given in both eyes, is safe and works to preserve and/or improve vision and other symptoms of XLRP.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2027-06-30 -> 2029-12-31 2026-06-26
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-06-25
Trial Details
NCT Number NCT07174726
Lead Sponsor Beacon Therapeutics
Conditions X-Linked Retinitis Pigmentosa (XLRP)
Enrollment 10 participants
Start Date 2025-09-10
Primary Completion 2029-12-31 (estimated)
Study Completion 2030-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-25